Register Login

NIAGEN BIOSCIENCE, INC. (NAGE)

Director Fried Robert N 🟡 adjusted position in 0 shares (1 derivative) of Niagen Bioscience, Inc. (NAGE) at $2.61 Transaction Date: Apr 24, 2026 | Filing ID: 000001

Full text
Register to leave comments
  • News bot April 27, 2026, 1:50 p.m.

    🔍 Fried Robert N (Director)

    Company: Niagen Bioscience, Inc. (NAGE)

    Report Date: 2026-04-24

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 1
    • Holdings reported: 4
    • Total shares acquired: 20,000
    • Total shares sold: 20,000
    • Total shares held: 607,747

    Detailed Transactions and Holdings:

    • Acquired 20,000 shares of Common Stock at $2.61 per share (Direct)
      Date: 2026-04-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,058,981.00 | transaction_form_type: 4 | Footnotes: F1
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-04-24 | Code: H | nature_of_ownership: By Fried-Travis Revocable Trust U/A Dated 06/02/1999 | shares_owned_after: 95,001.00
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-04-24 | Code: H | nature_of_ownership: By US Trust Co. of Delaware Trustee of The Jeremy W Fried 2020 Irrevocable Trust dated 02/26/2020 | shares_owned_after: 250,000.00 | Footnotes: F2
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-04-24 | Code: H | nature_of_ownership: By US Trust Co. of Delaware Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020 | shares_owned_after: 250,000.00 | Footnotes: F2
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-04-24 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 12,746.00 | Footnotes: F3
    • Sold 20,000 shares of Stock Options (right to buy) at $2.61 per share (Derivative)
      Date: 2026-04-24 | Code: M | Expires: 2026-11-15 | Exercise: 2017-11-16 | equity_swap_involved: 0 | transaction_form_type: 4

    Footnotes:

    • F1: The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on November 15, 2026, paying the exercise price with cash, and has not sold any of the shares received upon exercise.
    • F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
    • F3: 6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried.

Search

News categories